Abstract: IMPACT NHL was a multicenter, observational study in adults with non-Hodgkin lymphoma receiving CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy with or without rituximab. Erythropoietin-stimulating agent treatment was given according to routine clinical practice and physician preference. In a subanalysis, outcomes were evaluated in 207 patients who received darbepoetin alfa (DA). The most common reason (81%) for initiating DA was low/declining hemoglobin (Hb) concentration. Mean (±standard deviation) duration of DA exposure was 8.8 ± 6.9 weeks (mean number of doses, 5.1 ± 4.6). Overall, 23% of patients had chemotherapy and DA treatment synchronized more than 75% of the time. At the time of DA initiation, 67% of patients had Hb concentrations in the guideline-recommended range (9-11 g/dl). Of 89 patients with Hb concentrations <10 g/dl at DA initiation and still receiving DA 5 weeks later, 92% (Kaplan-Meier) achieved Hb concentrations 10-12 g/dl between week 5 and at the end of treatment. 
Introduction
Hemoglobin (Hb) concentrations <8 g/dL have been reported in 13-25% of patients receiving CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy, with or without rituximab, every 14 ([±R]CHOP-14) or 21 days ([±R]CHOP-21) [1] [2] [3] . Current treatment guidelines -such as those of the European Organisation for Research and Treatment of Cancer (EORTC) [4, 5] -state that treatment with an erythropoietin-stimulating agent (ESA) may be initiated when Hb concentrations fall to 9-11 g/dL in patients displaying anemia-related symptoms; the aim of ESA treatment is to restore the Hb concentration to a level no greater than 12 g/dL.
Methods
IMPACT NHL was a multicenter, observational study of neutropenia prophylaxis and management [6] , and anemia management, in adult patients with non-Hodgkin lymphoma receiving (±R)CHOP chemotherapy. Anemia-related outcomes in patients receiving any ESA have been reported previously [7] . Overall, 22% of patients received an ESA, of whom 51% received darbepoetin alfa (DA), compared with 48% who received epoetin. DA has a serum half-life that makes less-frequent administration possible [8] , and the dosing recommendations differ from those of epoetin-alfa and -beta in their respective Summaries of Product Characteristics. Therefore, data from IMPACT NHL for those patients who received DA were analyzed separately.
IMPACT NHL was conducted in 14 European countries and Australia Details of the study design have been presented previously [6] .
ESA treatment was given according to routine clinical practice and physician preference.
Patients could switch to a different ESA at any time, but were categorized for analysis according to the first ESA they received, with data after the switch excluded from the analysis. The present analysis included patients who received DA (either every 7 days or 21 days) as their first ESA.
Patients were adults (age ≥18 years) diagnosed with any histologic type of NHL. All patients were planned to receive at least three 14-or 21-day cycles of (±R)CHOP. For patients enrolled retrospectively, eligibility was assessed on the profile at the time treatment was planned, not on outcome or number of delivered cycles.
The study was conducted in accordance with the principles of the Declaration of Helsinki and approved by ethics committees and institutional review boards at all participating centers.
Written informed consent was obtained from all patients where required.
The full analysis set (FAS) included all patients who started at least one cycle of (±R)CHOP and provided data. Anemia-related outcomes included ESA exposure and change in Hb concentration after receiving ESA treatment. In addition, requirement for blood transfusion was evaluated in a subset of patients who were enrolled in the study for at least 29 days (including the day of ESA initiation) after starting ESA treatment.
The statistical analysis was descriptive in nature. Categorical data were summarized by the number and percentage of patients in each category, with summary statistics generated for continuous data. For patients who received one or more transfusions, data on Hb concentrations were disregarded for 28 days post-transfusion. For most patients, the reason for initiating DA, as specified by the treating physician (more than one reason could be specified), was a low or declining Hb concentration (n=167; 81%) and/or to reduce the risk of chemotherapy-induced anemia (n=45; 22%). Other reasons included evidence-based guidelines (n=7; 3%) and other anemia-related symptoms (n=1; 0.5%). The mean (±SD) duration of DA exposure was 8.8±6.9 weeks and the mean number of doses was 5.1±4.6. Patients made an average of six clinic visits per month, of which two visits, on average, were for DA treatment only (Table 1) . Overall, 48 patients (23%) had chemotherapy and DA treatment synchronized more than 75% of the time. 
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Discussion
Overall, the results of this observational study show that DA provided good control of Hb concentrations for most patients, with a quarter of patients experiencing an excess rate of Hb rise. Hb concentration at the time of initiation was in the range 9-11 g/dL in 67% of patients, which is consistent with the guidelines of the EORTC at the time of the study [4, 5, 9] . Thus, one-third of patients started DA at concentrations outside the recommended range, including 14% who initiated DA at concentrations below 9 g/dL.
The summaries of Hb concentration at DA initiation in this analysis were based on all patients within the DA-treated set and cannot, therefore, be compared directly with the published data for the ESA-treated study population, for which percentages were based on the number of patients with available Hb results. The results of patients receiving DA did, however, appear broadly similar to those of patients receiving other ESAs in the overall study population, in which 65% of patients had Hb concentrations of 9-11 g/dL when ESA treatment was initiated, and where 89% (95% CI: 78-101; Kaplan-Meier percentage) of patients achieved Hb concentrations 10-12 g/dL between week 5 and the end of the treatment period [7] . The results of the present analysis are also consistent with older observational studies of ESA treatment [10, 11] . As IMPACT NHL was an observational study, and included patients enrolled retrospectively, the results should be interpreted with the appropriate caution.
One issue that deserves consideration in the light of our data, in which some patients experienced Hb overshoot and others began DA treatment at a non-indicated baseline Hb level, is the potential for excess disease progression and/or mortality, as raised in previous publications [12, 13] . More recent studies, however, contradict this hypothesis. For example, in a pooled analysis of randomized, double-blind, placebo-controlled trials in patients with chemotherapy-induced anemia receiving DA or placebo (n=2122), DA had no impact on mortality, progression-free survival or disease progression [14] . Similarly, three metaanalyses -one of studies in patients with lymphoproliferative malignancies [15] , one in patients with lung cancer [16] and one broader analysis of oncology studies [17] -found no effect of ESAs on survival or disease progression.
In conclusion, this observational study found that DA was initiated most frequently in response to low or declining Hb concentrations. Hb concentration at the time of initiation was consistent with current EORTC guidelines in two-thirds of patients. Most patients who had Hb <10 g/dL when DA was initiated achieved stable target Hb concentrations of 10-12 g/dL by the end of the treatment period. Overall, we believe that the results of this analysis provide useful information for clinicians considering DA treatment for those patients with NHL who are receiving chemotherapy and have developed anemia.
